/
INMB
$2.08+$0.04 (+1.96%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$56.6M
28M shares
52-week range
$1.09 – $2.58
66% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-14.80
INmune Bio Inc. Common stock
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
www.inmunebio.com- Employees
- 21
- IPO / List date
- Feb 4, 2019
- HQ
- BOCA RATON, FL
Held by traders on TradeandTell
No one on the platform currently holds INMB.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 17,000 | $19.2K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded INMB yet.
